Cancer ResearchAkkermansia Shows Early Promise Against Immunotherapy-Resistant Colorectal Cancer
A gut bacterium may help immunotherapy work against a common form of colorectal cancer that usually resists it. Researchers found that oral Akkermansia muciniphila reduced tumor development and improved responses to an immune therapy in mice. The bacterium slowed immune cells' cleanup of dying cancer cells, triggering signals that strengthened cancer-fighting immune activity. In a phase 1 trial, patients with previously treated, metastatic colorectal cancer received Akkermansia probiotics alongside an antibody targeting PD-1. The authors reported that the combination was safe and produced measurable tumor shrinkage in 19% of patients. These results are encouraging but do not establish that the probiotic improves survival or works independently. The abstract does not provide patient numbers, detailed side effects, or response duration. Patients should not add probiotics to cancer treatment without their oncology team's guidance.
